Treatment of hepatitis C in patients with HIV coinfection: Efficacy and tolerance;Traitement de l'hépatite chronique C chez les malades ayant une co-infection VIH: Efficacité et tolérance

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Pol, Stanislas ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; INDINAVIR; INTERFERON; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

CHRONIC HEPATITIS; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME TESTS; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INFANT, NEWBORN; INTERFERONS; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDIES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RIBAVIRIN; TIME FACTORS; TRANSAMINASES;

EID: 0036262382     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (109)

1. Epidémiologie hospitalière des patients coinfectés par le VIH et le VHC
2. Progression and clinical outcome of infection due to human immunodeficiency virus
3. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
4. Coinfection of hepatitis C virus with immunodeficiency virus and progression to AIDS
5. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to survival
6. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users
7. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival
8. Does hepatitis C virus coinfection accelerate clinical and immunological evolution of HIV-infected patients?
9. The association between hepatitis C virus and immunodeficiency virus disease progression in a cohort of hemophilic men
10. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection
11. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections
12. High hepatitis viremia and impaired antibody response in patients coinfected with HIV
13. Hepatitis C virus (HCV) viremia in Human Immuno-deficiency Virus-seronegative and seropositive patients with indeterminate HCV recombinant immunoblot assay
14. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
15. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d'experts. Rapport 1999 sous la direction du Professeur J-F Delfraissy. Médecine-Sciences
16. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter hemophilia cohort study
17. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users
18. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia
19. Maternal-infant transmission of hepatitis C virus and HIV infections: A possible interaction
20. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study
21. Heterosexual cotransmission of hepatitis C virus and human immunodeficiency virus
22. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings
23. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation
24. Rapidly progressive Non-A, Non-B hepatitis in patients with human immunodeficiency virus infection
25. The natural history of parenterally-acquired chronic hepatitis C
26. Human immunodeficiency virus infection modifies the natural history of chronic parenterraly-acquired hepatitis C with an unusually rapid progression to cirrhosis
27. Liver fibrosis progression in HIV-HCV coinfected patients
28. The progression of HCV-associated liver disease in a cohort of haemophilic patients
29. The natural history of chronic hepatitis C in haemophiliacs
30. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
31. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs
32. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A longterm retrospective cohort study
33. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis
34. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
35. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: A case-control study
36. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy
37. A national survey in the departments of internal medicine and infectious diseases
38. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departmentqs of Internal Medicine/Infectious Diseases, in 1995 and 1997
39. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
40. Antiretroviral drugs for AIDS
41. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C
42. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
43. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection
44. Mortality for liver disease in patients with HIV infection: A cohort study
45. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
46. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C
47. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
48. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
49. Hepatitis C virus associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
50. Rapidly evolving hepatitis C virus-associated cirrhosis in HIV coinfected patient in relation to antiretroviral tritherapy
51. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: Differences between complete and partial virologic responders?
52. Anti-HIV tritherapy does not modify HCV replication in coinfected subjects
53. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy
54. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-coinfected haemophiliacs
55. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
56. Fulminant hepatic failure associated with 2′, 3′ dideoxyinosine (ddI)
57. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worlwide, 1997-2000
58. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
59. Severe hepatic cytolysis in patients treated by highly active antiretroviral therapy (HAART) with protease inhibitor or with two nucleoside reverse transcriptase inhibitors (NRTIs)
60. Severe hepatitis in three AIDS patients treated by indinavir
61. Elevated liver enzymes following initiation of antiretroviral therapy
62. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
63. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART
64. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection
65. Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients
66. Treatment of chronic hepatitis C with recombinant interferon alpha
67. Hepatitis C virus type 1b (II) infection in France and Italy
68. Treatment of special populations
69. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus
70. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs
71. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count
72. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
73. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients
74. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: Efficacy, tolerance, and response related factors
75. Aggressive daily interferon therapy in HIV-HCV coinfected patients
76. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients
77. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study
78. Rapid decline of CD4+ cells after interferon alpha treatment in HIV-1 infection
79. CD4+ T Lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C
80. Randomized trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
81. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
82. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
83. EASL International Consensus Conference on hepatitis C 26-27 February 1999, Paris, France
84. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
85. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
86. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders
87. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
88. Long-term efficacy of combination therapy with interferon-alpha-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
89. Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients
90. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment
91. Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin
92. Chronic hepatitis C in HIV-coinfected patients: Feasibility and efficacy of interferon-alpha-2b and ribavirin combination therapy
93. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
94. Effect of interferon and ribavirin on HIV viral load
95. Ribavirin antagonizes the effect of azidothymidine on HIV replication
96. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy
97. A highly synergistic tripe antiviral combination with potential activity against both HIV and hepatitis C viruses
98. Combination treatment for hepatitis C can be hazardous in patients coinfected with HIV
99. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
100. Mitochondrial toxic effects and ribavirin
101. Pilot study of interferon-alpha with and without amantadine for the treatment of hepatitis C in HIV coinfected individuals on antiretroviral therapy
102. Recombinant interleukin 2 for treatment of HIV reduces hepatitis C viral load in coinfected patients
103. Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus coinfected patients
104. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
105. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa
106. Modeling the impact of interferon alfa treatement on liver fibrosis progression in chronic hepatitis C: A dynamic view
107. Interaction between nelfinavir and tacrolimus after orthotopic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV)
108. Liver transplantation in adults coinfected with HIV
109. Impact of HIV coinfection on the long-term follow-up of HCV-related cirrhosis